Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 05, 2019 16:05 ET | Source: VIVUS, Inc.

VIVUS Reports Third Quarter 2019 Financial Results

CAMPBELL, Calif., Nov. 05, 2019 (GLOBE NEWSWIRE) -- VIVUS, Inc. (NASDAQ: VVUS) (the “Company”), a specialty pharmaceutical company committed to the development and commercialization of innovative...
October 28, 2019 07:30 ET | Source: VIVUS, Inc.

VIVUS Announces Departures of Eric W. Roberts and Allan L. Shaw from Board of Directors

CAMPBELL, Calif., Oct. 28, 2019 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS) (the “Company”), a biopharmaceutical company, announced today that Eric W. Roberts and Allan L. Shaw have resigned from...
October 22, 2019 07:30 ET | Source: VIVUS, Inc.

VIVUS to Host Third Quarter Business Update and Financial Results Conference Call on Tuesday, November 5, 2019

CAMPBELL, Calif., Oct. 22, 2019 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS) today announced that it will report financial results and provide a business update for the third quarter of 2019 after...
October 21, 2019 07:30 ET | Source: VIVUS, Inc.

VIVUS to Highlight Integrated Approach to More Effective Weight Management in Panel Discussion at the Cleveland Clinic 2019 Medical Innovation Summit

CAMPBELL, Calif., Oct. 21, 2019 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS) (the “Company”), a biopharmaceutical company, announced today that John Amos, Chief Executive Officer, will participate...
October 07, 2019 07:30 ET | Source: VIVUS, Inc.

VIVUS Announces Acceptance of Qsymia Decentralized Marketing Authorization Application in Europe

CAMPBELL, Calif., Oct. 07, 2019 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS) (the “Company”), a biopharmaceutical company, announced today that European regulatory agencies in Sweden, Denmark,...
October 03, 2019 07:30 ET | Source: VIVUS, Inc.

VIVUS Initiates Pay Down of Secured Debt and Announces Management Changes

-Reduction of $48.6 million of Secured Debt will result in total interest savings of $10.5 million--Organizational change streamlines commercial operations- CAMPBELL, Calif., Oct. 03, 2019 ...
August 28, 2019 07:30 ET | Source: VIVUS, Inc.

VIVUS to Present at Upcoming Conferences

CAMPBELL, Calif., Aug. 28, 2019 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS) (the “Company”), a biopharmaceutical company, today announced that John Amos, Chief Executive Officer at VIVUS, will...
August 27, 2019 07:30 ET | Source: VIVUS, Inc.

VIVUS to Share Qsymia® Safety and Efficacy Data with a Global Audience at ICOMES & AOCO 2019

-Conference in Seoul provides opportunity to introduce an international audience to the clinical safety and benefits of Qsymia following its approval in the Republic of Korea- CAMPBELL, Calif., Aug. ...
August 20, 2019 07:30 ET | Source: VIVUS, Inc.

New Pilot Clinical Study Results Demonstrate that Addition of VIVUS’ Qsymia® to Gastric Sleeve Surgery Significantly Improves Weight Loss Compared with Surgery Alone

-Data published in Surgery for Obesity and Related Diseases also show that patients in the Qsymia group lost more than twice as much weight during preoperative treatment compared with control group- ...
August 06, 2019 16:05 ET | Source: VIVUS, Inc.

VIVUS Reports Second Quarter 2019 Financial Results

CAMPBELL, Calif., Aug. 06, 2019 (GLOBE NEWSWIRE) -- VIVUS, Inc. (NASDAQ: VVUS) (the “Company”), a specialty pharmaceutical company committed to the development and commercialization of innovative...